# 1. Financial Performance ## A. Key Figures * **Stand-alone Revenue:** **₹425 Cr** Q3 FY26 (-10% YoY) · **₹471 Cr** Q3 FY25 * **EBITDA:** **₹103 Cr** Q3 FY26 (-10% YoY) · **₹115 Cr** Q3 FY25 * **PAT:** **₹44 Cr** Q3 FY26 (-41% YoY) · **₹74 Cr** Q3 FY25 * **Gross Debt:** **₹650 Cr** (9M FY26) * **Net Debt:** **₹650 Cr** Q3 FY26 (minimal cash) ## B. Revenue & Growth * **Revenue Deferral Impact:** Q3 top-line and profitability were meaningfully impacted by **INR49 Cr** of unbooked sales due to DAP incoterms, representing a **one-off timing delay** in revenue recognition. * **Normalization Expected:** The deferred consignment will contribute **INR49 Cr revenue** and **INR19 Cr PBT** in Q4, supporting a strong sequential rebound. * **Export & API Trends:** Export shipments were limited in first three quarters; API revenue has stabilized at **INR150–160 Cr/quarter**, moderating from prior highs. * **Incoterm Dynamics:** Most revenue is recognized at shipment (CIF/FOB), but isolated DAP contracts cause delivery-linked deferrals—typically, transit delays are short due to air freight dominance. ## C. Profitability Trends * **Margin Pressure:** Profitability decline driven by lower volumes and **full absorption of Atali’s depreciation and opex**, including **INR25 Cr/quarter** in depreciation from **INR300 Cr capex**. * **Stable Gross Margins:** Despite quarterly volatility, **9-month trend indicates stable gross margins**, with management affirming sustainability absent one-off distortions. * **Opex Outlook:** Other expenses expected to normalize to **21%–22% of sales** as Atali ramps and revenue scales, offsetting current high fixed-cost drag. ## D. Balance Sheet & Cash Flow * **Debt Position:** Maintains **₹650 Cr gross and net debt** with minimal cash; net debt/equity expected to settle between **3.0x–3.5x** by year-end. * **Working Capital:** **INR30 Cr stock in transit** reflects deferred consignment; normal transit stock is **INR10–12 Cr**, primarily dockside finished goods. * **Forex & Opex:** **Net forex impact neutral (~INR5 Cr)** due to offsetting export gains and import/loan losses; **monthly opex run rate at INR5 Cr**. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue Mix:** **49%** Xanthine Derivatives · **39%** API & Intermediates · **12%** CDMO/CMO ## B. API & Intermediates * **Ongoing Margin Pressure:** API & intermediates face headwinds despite early signs of recovery, with majority of sales in regulated markets. * **Growth Catalysts Ahead:** New API launches (Apixaban, anticancer) planned for 2026 and patent expiries in 2027–2028 expected to boost performance in FY2026–27. * **Capacity Constraints:** Subdued volume growth due to limited intermediate production, as facility prioritized CDMO output. ## C. CDMO/CMO Business * **Strategic Reboot:** New CSO driving revised strategy to capture oncology pipeline earlier and expand market footprint. * **Q4 EBITDA Surge Expected:** Driven by high CDMO sales volume and **₹49 Cr** deferred revenue recognition. * **High-Growth Potential:** Small base implies **1–2 major deals** could significantly scale business; agnostic partnership model leverages chemistry expertise across innovators and biotechs. ## D. Xanthine Derivatives * **Market Positioning Goal:** Management aims to be **top 3 globally by capacity** to strengthen competitive standing. * **Sales & Volume Mix:** Majority of volumes (63%) serve beverage customers; exports account for 51% of segment sales. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Atali Capex:** **₹300 Cr** capitalized of **₹450 Cr** total approved (₹150 Cr remaining) * **Xanthine Capex:** **₹150 Cr** total approved across both sites * **Current Xanthine Capacity:** **500 MT/month** (6,000 MT/year), expanding to **800 MT/month** (9,600 MT/year) * **Near-Term Output Target:** Atali capacity debottlenecked to **6,000 units/quarter**, path to **7,000–7,500 units** ## B. Atali Plant Ramp-up * **Commercial Launch Achieved:** Phase 1 operations underway with large equipment enabling **much larger batch sizes**, despite initial ramp-up hiccups now being resolved. * **Capacity Expansion in Progress:** Additional products to be validated in FY27, increasing intermediates output; **at least one new block** planned for FY27 with **minimal incremental capex**. * **Cost Pressures Emerge:** Rising opex driven by Atali and leased site fees; upfront costs incurred in Q3 for expansion activities. ## C. Xanthine Expansion * **On Schedule for FY27 Ramp-Up:** Mechanical completion expected by March '26; incremental capacity of **300 MT/month** to come online in Q1 FY27. * **Post-Expansion Capacity to Reach 9,600 Tonnes Annually,** with utilization expected to grow progressively to **50–60% average** and similar exit rate. * **Full Commercial Scale Targeted:** Xanthine project to reach **full capacity of 9,000 tonnes per annum** by end of Q4, aligning with demand ramp. ## D. Capacity Utilization * **Multi-Block De-Bottlenecking Underway:** Completed expansion in Block 5; debottlenecking planned for **steroid and oncology blocks** to unlock incremental sales from validated products. * **Long-Term Utilization Target Set:** Aims to operate at **85–90% of total installed capacity by FY28**, equating to **7,200–8,640 tonnes annually**, while preserving buffer headroom. --- # 4. Customer & Project Metrics ## A. Key Figures * **CDMO Revenue Contribution:** **12%** of quarterly revenue * **Active CDMO Customers:** **21** * **Ongoing CDMO Projects:** **59** (40 commercial, 19 development) * **Commercial Projects:** Increased from **33 to 40** over 9 months * **Commercial Molecules:** Grew from **28 to nearly 40** * **Locked-in Business:** ~**50%** of CDMO revenue on average * **Key Project Concentration:** **7–8 projects** drive **80%** of CDMO sales * **Wallet Share:** Up to **70%** of intermediates supplied for select innovator partners ## B. CDMO Pipeline * **Pipeline Maturation:** Strong expansion in commercial-stage projects reflects successful development conversions and a dynamic, high-quality pipeline. * **Revenue Visibility:** Nearly **half of CDMO revenue is locked in**, with critical demand signals expected in Q4 (Jan–Mar), supporting forward visibility. * **New Momentum:** Robust BD activity generating new inquiries and RFP responses, with confidence in winning upcoming bids. ## C. Key Customers * **Blockbuster Catalyst:** Partner **Bayer secured U.S. FDA approval** for a product with **€1B sales potential**, marking a major commercial inflection point. * **Strategic Deepening:** Increased direct engagement with innovators and expanded **wallet share (60–70%)** highlight growing strategic importance and integration. * **Transaction Scale:** Single POs in the **single-digit million-dollar range** confirm material project scale and customer trust. ## D. Commercial Projects * **Near-Term Revenue Upside:** **Q4 expected to see significant export shipments** of newly commercialized products, boosting near-term revenue realization. * **Supply Chain Agility:** High-value products shipped **by air (5–8 days)** for speed, while sea freight used for cost efficiency despite longer lead times. --- # 5. Pricing & Demand Trends ## A. Key Figures * **Xanthine Price Trend:** **+5%** spot price recovery from lows · **+8% to +10%** expected global increase * **Trade Advantages:** **13%** Chinese rebate eliminated · **20%** U.S. duty on Chinese caffeine · **Duty-free** access for Indian exports ## B. API Pricing * **Structural Pricing Pressure:** API segment faces ongoing pricing de-growth, consistent with industry trends, driven by high prior-year order volumes and lack of pricing power in generic APT markets. * **Competitive Resilience:** Where competing with China, the company maintains margin advantages supported by rupee depreciation, though contract structures delay full benefit realization. ## C. Xanthine Market * **Favorable Supply Shift:** Removal of Chinese export rebates has rebalanced global competitiveness, removing a **13% cost advantage** and creating tailwinds for non-Chinese producers. * **Pricing Recovery Underway:** Spot prices have turned upward, confirming a bottom, with further increases anticipated due to structural trade advantages and tightening supply dynamics. --- # 6. Operational & Regulatory Risks ## A. Plant Ramp-up Delays * **Resolution in Progress:** Operational challenges at the Atali site—driven by newer staff and setup complexities during product validation—are being addressed with strengthened teams; full resolution expected by end of Q4. * **Production Shift Imminent:** Successful resolution paves the way for **intermediate production transfer from Vapi to Atali starting Q1**, marking a key step in site utilization ramp-up. ## B. Regulatory Dependencies * **Staggered Approval Timeline:** Regulatory clearances across markets are **not synchronized**, with no Day 1 approval expected globally due to divergent agency review cycles. --- # 7. Guidance & Outlook ## A. Key Figures * **CDMO Revenue Target:** **₹1,000 Cr** FY26 target maintained, FY27 growth expected to mirror FY26 performance * **EBITDA Growth:** Flat to **marginal growth** in FY26; **50–55% QoQ jump** expected in Q4 * **API Revenue:** Target to exceed **₹200 Cr quarterly** in coming quarters ## B. CDMO Revenue Target * **FY26 Target Intact, Upside Unlikely:** CDMO revenue guidance for FY26 remains achievable despite **project delivery delays of a few months**, though outperformance is now off the table. * **Pipeline Supports Confidence:** Visibility into CDMO ramp-up is strong post-first block commissioning, bolstered by **multiple large-scale commercial products** and **projects with ₹100–150 Cr revenue potential**. * **FY27 Growth Anticipated, Guidance Pending:** Management expects **good growth in CDMO/CMO business for FY27**, with formal guidance to follow after March budget finalization. * **Revenue Dependent on Partner Success:** CDMO ramp-up trajectory remains contingent on **partner drug launch performance and market adoption**, with typical **first-year sales dip** followed by multi-year recovery. ## C. FY27 Growth Expectations * **Near-Term EBITDA Pressure, Back-Loaded Recovery:** EBITDA to be flat YoY in FY26 due to **API de-growth and CDMO delays**, with most growth concentrated in Q4. * **Margins on Track to Re-Rate:** High-margin performance seen previously is sustainable; **similar EBITDA margins possible in FY27** if CDMO/CMO sales grow at **30–40%** as planned. * **API Recovery Phased:** Return to **₹200 Cr+ quarterly API revenue** expected over the next few quarters, though not in the immediate term, driven by new product launches. * **Customer Expansion Ahead:** CDMO customer base expected to grow in **calendar year 2026**, supporting future revenue diversification.